Journal
MOLECULES
Volume 26, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/molecules26040841
Keywords
G-quadruplex; telomerase inhibition; proto-oncogene promoters; ribosomal DNA; anticancer agents; small-molecule ligands
Funding
- University of Cyprus
Ask authors/readers for more resources
G-quadruplexes, a family of tetraplex helical nucleic acid topologies, have shown potential for anticancer research due to their presence in functionally-important regions of the human genome and their ability to exert anticancer effects. Despite only a few lead compounds progressing to clinical trials, recent advancements in the field have created conditions for further development of drug candidates targeting G-quadruplexes.
G-quadruplexes, a family of tetraplex helical nucleic acid topologies, have emerged in recent years as novel targets, with untapped potential for anticancer research. Their potential stems from the fact that G-quadruplexes occur in functionally-important regions of the human genome, such as the telomere tandem sequences, several proto-oncogene promoters, other regulatory regions and sequences of DNA (e.g., rDNA), as well as in mRNAs encoding for proteins with roles in tumorigenesis. Modulation of G-quadruplexes, via interaction with high-affinity ligands, leads to their stabilization, with numerous observed anticancer effects. Despite the fact that only a few lead compounds for G-quadruplex modulation have progressed to clinical trials so far, recent advancements in the field now create conditions that foster further development of drug candidates. This review highlights biological processes through which G-quadruplexes can exert their anticancer effects and describes, via selected case studies, progress of the last few years on the development of efficient and drug-like G-quadruplex-targeted ligands, intended to harness the anticancer potential offered by G-quadruplexes. The review finally provides a critical discussion of perceived challenges and limitations that have previously hampered the progression of G-quadruplex-targeted lead compounds to clinical trials, concluding with an optimistic future outlook.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available